Brett King, MD, PhD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, CT
Rodney D. Sinclair, MBBS, MD, FACD
Professor of Medicine,
University of Melbourne
Director of Dermatology and Epworth Healthcare Director, Sinclair Dermatology
East Melbourne, Australia
This case-based activity targets healthcare gaps related to the underlying autoimmune causes of alopecia areata (AA) and targeted treatment approaches, which can have a profound impact on health-related quality of life through burden of disease and associated comorbidities. This content was co-created by Dr. Brett King (New Haven, CT) and Dr. Rodney Sinclair (Melbourne, Australia).
- By addressing these gaps, you can assess whether your approach to AA management through utilization of immune-related targeted treatment approaches and comorbidity assessment – could be modified to help close these gaps.
- Expert discussion will guide you in analyzing and identifying appropriate candidates for immune-targeted treatment of alopecia with JAK inhibitors, as well as assessment and management strategies for associated comorbidities.
- You will also be immersed in dynamic animations utilizing a whiteboard platform to memorably highlight key points related to immune pathways in the development of alopecia areata and patient counseling techniques for tailored disease and comorbidity management.
This educational activity is intended for dermatology professionals who care for patients with AA.
- Elucidate the immune pathways involved in the pathogenesis of alopecia areata (AA) and their implications for targeted treatment
- Identify patients who may potentially benefit from Janus kinase (JAK) inhibitors for the treatment of AA based on clinical trial data on their efficacy and safety
- Select optimal approaches for identifying and addressing the physical and psychological comorbidities of AA
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 1.25 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the therapeutic management of patients with AA.
CNE Credits: 1.25 ANCC Contact Hour(s).
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Brett King, MD, PhD has received consulting fees from Aclaris Therapeutics, Almirall, Arena Pharmaceuticals, Bristol-Meyers Squibb Co, Concert Pharmaceuticals, Dermavant Sciences, Eli Lilly, Pfizer, and Viela Bio, served on speakers bureaus for Regeneron and Sanofi Genzyme, and served as an investigator for Arena Pharmaceuticals, Concert Pharmaceuticals, Eli Lilly, NIH, and Pfizer.
Rodney D. Sinclair, MBBS, MD, FACD has served on an advisory board Eli Lily, Leo Pharma, Pfizer, and Samson, speakers bureaus for Bayer, Eli Lilly, Pfizer, and Novartis, consulted for Ascend Therapeutics and CSL Limited, and contracted research for AbbVie, Amgen, Ascend Therapeutics, Astra Zeneca, Boehringer Ingelheim, Celgene, Coherus BioSciences, Dermira, Eil Lilly, Galderma, GSK, InVentiv Health Pharmaceuticals, Janssen Cilag, Johnson and Johnson, InVentiv Health Pharmaceuticals, Medimmune, Medpace, Merck, Novartis, Pfizer, Principia, Regeneron, Reistone Biopharma, and Sun Pharma.
CME Content Review
CNE Content Review
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the activity.
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: February 25, 2021
EXPIRATION DATE: February 25, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected].
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.